繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

应用DNA科学GAAP每股收益为-0.32美元,落后0.02美元,收入为81万美元,落后0.09万美元

2024-12-18 05:35

  • Applied DNA Sciences press release (NASDAQ:APDN): Q4 GAAP EPS of -$0.32 beats by $0.02.
  • Revenue of $0.81M (+3.8% Y/Y) misses by $0.09M.
  • Adjusted EBITDA for the fourth quarter of fiscal 2024 was a negative $3.2 million compared with a negative $3.5 million in the prior year period.
  • Cash and cash equivalents on September 30, 2024, totaled $6.4 million. On October 31, 2024, the Company completed a registered direct offering and received net proceeds of approximately $5.8 million after deducting placement agent fees and other estimated offering costs payable by the Company. As a result of this offering, cash and cash equivalents as of November 3, 2024, were approximately $10.1 million.
  • Shares -25.65%.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。